Two signals from one molecule
GIP stands for glucose-dependent insulinotropic polypeptide. GLP-1 stands for glucagon-like peptide-1. Both belong to a hormone system involved in the body's response to food. Tirzepatide is a single manufactured molecule designed to switch on both receptors. The pen does not contain two separate drugs mixed together.
Receptors are docking points which let a chemical signal act on a cell. Switching on these receptors changes several processes, including glucose control and appetite. No single instruction, such as blocking carbohydrate absorption, sums up the effect. Tirzepatide does not remove calories already eaten, and you still need good nutrition.
What happens to blood glucose
Tirzepatide raises insulin release in a glucose-dependent way and acts on glucagon, another hormone involved in glucose control. Glucose-dependent means the effect varies with your glucose level. Low blood glucose is still possible. The risk rises when you also use insulin or sulphonylureas.
If you have type 2 diabetes, better glucose control is a treatment outcome in its own right, separate from weight loss. You may see meaningful glucose changes before large changes on the scales. Your diabetes medicines and monitoring may need review even when weight loss looks modest.
Why hunger and fullness change
The medicine acts on pathways involved in eating and feeling full. Many people notice less hunger, feel satisfied sooner during meals or think about food less. These effects vary from person to person. Food noise is a phrase patients use. No laboratory test or formal measure of food noise sets the correct dose.
A quieter appetite should still leave room for regular meals. Feeling unable to eat, vomiting repeatedly or becoming frightened of food are not treatment goals. A clinician or dietitian can help you tell a manageable change in appetite from a pattern which threatens your nutrition or recovery from an eating disorder.
Slower stomach emptying
Tirzepatide delays gastric emptying, so food leaves the stomach more slowly. This adds to fullness and to digestive symptoms. The effect matters most when treatment starts. Slower emptying also affects how fast some oral medicines are absorbed. It also matters before procedures involving deep sedation or general anaesthesia.
Slower emptying does not mean everyone on Mounjaro has gastroparesis. Persistent severe symptoms need a medical assessment, and an internet explanation will not identify the cause. Equally, no nausea does not mean the receptors have stopped responding.
Why one weekly injection lasts the week
The molecule stays in the body long enough to support weekly dosing. Drug levels rise and fall gradually across the week. They do not switch off at midnight on injection day. Hunger changing during the week is no reason for an extra injection or a shorter gap between doses.
The mechanism shows why the medicine is biologically plausible. Trials are what show real benefits and harms. Two receptor targets do not make a medicine twice as effective as one with a single target. Milligram strength is no universal scale across GLP-1 medicines.
Sources
Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.
- Mounjaro UK Summary of Product Characteristics, updated September 2026 medicines.org.uk
- NHS: tirzepatide nhs.uk
- SURMOUNT-1: tirzepatide once weekly for obesity pubmed.ncbi.nlm.nih.gov
Spotted something out of date? Report a mistake.